Mitochondrial damage: A possible mechanism of the 'topical' phase of NSAID induced injury to the rat intestine

Gut

Volumn 41, Issue 3, 1997, Pages 344-353

  Somasundaram, S ^a   Rafi, S ^a   Hayllar, J ^a   Sigthorsson, G ^a   Jacob, M ^a   Price, A B ^b   Macpherson, A ^a   Mahmod, T ^a   Scott, D ^a   Wrigglesworth, J M ^c   Bjarnason, I ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ST MARK S HOSPITAL   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Drug induced toxicity; Intestinal inflammation; Intestinal toxicity; Mitochondrial function

Indexed keywords

6 METHOXY 2 NAPHTHYLACETIC ACID; ACETYLSALICYLIC ACID; FLURBIPROFEN; INDOMETACIN; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PIROXICAM; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG INDUCED DISEASE; ELECTRON MICROSCOPY; ENTERITIS; INTESTINE INJURY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MITOCHONDRION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; RAT;

EID: 9844219743     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.41.3.344     Document Type: Article

References (58)

1. Barrier CH, Hirschowitz BI. Current controversies in rheumatology. Controversies and management of non-steroidal anti-inflammatory drug induced side effects on upper gastrointestinal tract. Arthritis Rheum 1989; 32: 926-9.
2. Bjarnason I, Hayllar J, Macpherson AJ, Russell AS. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine. Gastroenterology 1993; 104: 1832-47.
3. Whittle BJR. Unwanted effects of aspirin and related agents on the gastrointestinal tract. In: Vane JR, Botting RM, eds. Aspirin and other salicylates. London: Chapman and Hall Medical, 1992: 465-509.
4. Wallace JL. The 1994 Merk Frost Award. Mechanism of nonsteroidal anti-inflammatory drug (NSAID) induced gastrointestinal damage-potential for development of gastrointestinal tract safe NSAIDs. Can J Physiol Pharmacol 1994; 72: 1493-9.
5. Rainsford KD, Whitehouse MW. Biochemical gastroprotection from acute by aspirin and related drugs. Biochem Pharmacol 1980; 29: 1281-9.
6. Somasundaram S, Hayllar J, Rafi S, Wrigglesworth J, Macpherson A, Bjarnason I. The biochemical basis of NSAID-induced damage to the gastrointestinal tract: A review and a hypothesis. Scand J Gastroenterol 1995; 30: 289-99.
7. Levine RA, Petokas S, Nandi J, Enthoven D. Effects of non-steroidal anti-inflammatory drugs on gastrointestinal injury and prostanoid generation in healthy volunteers. Dig Dis Sci 1988; 33: 660-6.
8. Ligumski M, Golanska EM, Hansen DG, Kauffman GL. Aspirin can inhibit gastric mucosal cyclo-oxygenase without causing lesions in the rat. Gastroenterology 1983; 84: 756-61.
9. Ivey KJ, Poane DB, Krause WJ. Acute effect of systemic aspirin on gastric mucosa in man. Dig Dis Sci 1980; 25: 97-9.
10. Langenbach R, Morham SG, Tiano HF, Loftin CD, Ghanayem BI, Chulada PC, et al. Prostaglandin synthase 1 gene disruption in mice reduced arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 1995; 83: 483-92.
11. Rainsford KD. Mechanisms of gastrointestinal toxicity of non-steroidal anti-inflammatory drugs. Scand J Gastroenterol 1989; 24 (suppl 163): 9-16.
12. Daneshmend TK, Stein AG, Bhaskar NK, Hawkey CJ. Abolition by omeprazole of aspirin induced gastric mucosal injury in man. Gut 1991; 31: 514-7.
13. Brookes PM, Day RO. Nonsteroidal antiinflammatory drugs-differences and similarities. N Eng J Med 1991; 324: 1716-25.
14. Brune K, Schwietzer A, Eckert H. Parietal cells of the stomach trap salicylates during absorption. Biochem Pharmacol 1977; 26: 1735-40.
15. Whitehouse MW. Biochemical properties of anti-inflammatory drugs-III. Uncoupling of oxidative phosphorylation in a connective tissue (cartilage) and liver mitochondria by salicylate analogues: relationship of structure to activity. Biochem Pharmacol 1964; 13: 319-36.
16. Mehlman MA, Tobin RB, Sporn EM. Oxidative phosphorylation and respiration by rat liver mitochondria from aspirin treated rats. Biochem Pharmacol 1972; 21: 3279-85.
17. Tokumitsu Y, Lee S, Ui M. In vitro effects of nonsteroidal antiinflammatory drugs on oxidative phosphorylation in rat liver mitochondria. Biochem Pharmacol 1977; 26: 2101-6.
18. Robins PG. Ultrastructural observations on the pathogenesis of aspirin-induced gastric erosions. Br J Exp Pathol 1980; 61: 497-504.
19. Peters TJ, Jones PE, Jenkins WJ, Wells JA. Analytical subcellular fractionation of jejunal biopsy specimens: enzyme activities, organelle pathology and responses to corticosteroids in patients with non-responsive coeliac disease. Clin Sci Mol Med 1978; 55: 293-300.
20. Peters TJ. Investigation of tissue organelles by a combination of analytical subcellular fractionation and enzymic microanalysis: a new approach to pathology. J Clin Pathol 1981; 34: 1-12.
21. Lowry OH, Rosebrough NR, Farr AL, Randall RJ. Protein measurement with folin-phenol reagent. J Biol Chem 1951; 193: 265-75.
22. Carter EA, Hatz RA, Yarmush ML, Tompkins RG. Injury-induced inhibition of small intestinal protein and nucleic acid synthesis. Gastroenterology 1990; 98: 1445-51.
23. Tyler DD. Respiratory enzyme systems of mitochondria. In: The mitochondria in health and disease. New York: VCH Publishers, 1991: 269-352.
24. Chance B, Williams GR. The respiratory chain and oxidative phosphorylation. Adv Enzymol 1956; 17: 65-134.
25. Wax J, Clinger WA, Varner P, Bass P, Winder CV. Relationship of the enterohepatic cycle to ulcerogenesis in the rat small bowel with flufenamic acid. Gastroenterology 1970; 58: 772-80.
26. Brodie DA, Cook PG, Bauer BJ, Dagleg E. Indomethacin-induced intestinal lesions in the rat. Toxicol Appl Pharmacol 1970; 17: 615-24.
27. Melrange R, Gentry C, O'Connor C, Blower PR, Neil C, Kelvin AS, et al. Antiinflammatory and gastrointestinal effects of nabumetone or its active metabolite, 6-methoxy-6-naphthylacetic acid (6MNA). Dig Dis Sci 1992; 37: 1847-52.
28. Insel PA. Analgesic-antipyretics and antiinflammatory agents: Drugs employed in the treatment of rheumatoid arthritis and gout. In: Gillman AG, Rall TW, Nies AS, Taylor P, eds. Goodman and Gilman's. The pharmacological basis of therapeutics. 8th edn. New York: McGraw-Hill, 1993: 638-81.
29. Kent TH, Cardeli RM, Stanler FU. Small intestinal ulcers and intestinal flora in rats given indomethacin. Am J Pathol 1969; 54: 237-45.
30. Anthony A, Dhillon AP, Nygard G, Hudson M, Piasecki C, Strong P, et al. Early histological features of small intestinal injury induced by indomethacin. Aliment Pharmacol Ther 1993; 7: 29-40.
31. Dudeja PK, Brasitus TA. Inactivation of rat small intestinal brush-border membrane alkaline phosphatase by oxygen free radicals. Gastroenterology 1993; 105: 357-66.
32. Wallace JL, Reuter B, Cicala C, McKnight W, Grisham MB, Cirino G. Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in rat. Gastroenterology 1994; 107: 173-9.
33. Ligumsky M, Grossman MI, Kauffman GL. Endogenous gastric mucosal prostaglandins: their role in mucosal integrity. Am J Physiol 1982; 242: G337-41.
34. Whittle BJR. Mechanism underlying gastric mucosal damage induced by indomethacin and bile salt, and the actions of prostaglandins. Br J Pharmacol 1977; 60: 455-60.
35. Whittle BJR. Protective mechanisms of the gastric mucosa. In: Gustsavsson S, Kumar D, Graham DY, eds. The stomach. Edinburgh: Churchill Livingstone, 1992: 81-101.
36. Baskin WN, Ivey KJ, Kraus WJ. Aspirin-induced ultrastructural changes in human gastric mucosa. Ann Intern Med 1976; 85: 299-303.
37. Lichtenberger LM, Wang Z-M, Romero JJ, Ulloa C, Perez JC, Giraud M-N, et al. Non-steroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids: Insight into the mechanism and reversal of NSAID-induced gastrointestinal injury. Nat Med 1995; 1: 154-8.
38. Gullikson GW, Cline WS, Lorenzson V, Benz L, Olsen WA, Bass P. Effects of anionic surfactants on hamster small intestinal membrane structure and function: relationship to surface activity. Gastroenterology 1977; 73: 501-11.
39. Gullikson GW, Sender M, Bass P. Laxative-like effects of nonsteroidal anti-inflammatory drugs on intestinal fluid movement and membrane integrity. J Pharmacol Exp Ther 1981; 220: 236-52.
40. Szabo S, Spill WF, Rainsford KD. Non-steroidal anti-inflammatory drug-induced gastropathy. Med Tox Adverse Drug Exp 1989; 4: 77-94.
41. Brune K, Dietzel K, Nurnberg B, Schneider H-Th. Recent insight into the mechanism of gastrointestinal tract ulceration. Scand J Rheumatol 1987; 16 (suppl 65): 135-40.
42. Adams SS, Cobb R. A possible basis for the anti-inflammatory activity of salicylates and other non-hormonal anti-rheumatic drugs. Nature 1958; 181: 773-74.
43. Ohe K, Hayashi K, Shirakawa J, Yamada K, Kawasaki T, Miyoshi A. Aspirin and taurocholate-induced metabolic damage in mammalian gastric mucosa in vitro. Am J Physiol 1980; 239: G457-62.
44. Spenny JG, Bhown M. Effect of prostaglandin acid on gastric mucosa. II. Mucosal ATP and phosphocreatinine content and salicylic effects on mitochondrial metabolism. Gastroenterology 1977; 73: 995-9.
45. Herbette LG, Vecchiarelli M, Trummlitz G. NSAID mechanism of action: the role of intracellular pharmacokinetics. In: Vane J, Botting J, Botting R, eds. Improved non-steroid anti-inflammatory drugs. COX-2 enzyme inhibitors. Dordrecht: Kluwer Academic Publishers, 1996: 85-102.
46. Garavito RM. The three-dimensional structure of cyclooxygenases. In: Vane J, Botting J, Botting R, eds. Improved non-steroid anti-inflammatory drugs. COX-2 enzyme inhibitors. Dordrecht: Kluwer Academic Publishers, 1996: 29-43.
47. Bugat R, Thompson MR, Aures D, Grossman MI. Gastric mucosal lesions produced by intravenous infusion of aspirin in cats. Gastroenterology 1976; 71: 754-9.
48. Kaufman GL, Grossman MI. Prostaglandin and cimethidine inhibit the formation of ulcers produced by parenteral salicylates. Gastroenterology 1978; 75: 1099-102.
49. Brett MA, Greb WH, Kurth HJ, Rulander G, Haddock RE, Thawley AR. Absence of enterohepatic circulation of the active metabolite of nabumetone. Forschr Med 1988; 106: 736-7.
50. Roth SH. New understandings of NSAID gastropathy. Scand J Rheumatol 1989; 19 (suppl 78): 24-9.
51. Eversmeyer W, Poland RE, DeLapp RE, Jensen CP. Safety experience with nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis. Am J Med 1993; 95: 10-9.
52. Bjarnason I, Fehilly B, Smethurst P, Menzies IS, Levi AJ. The importance of local versus systemic effects of non-steroidal anti-inflammatory drugs to increase intestinal permeability in man. Gut 1991; 32: 275-7.
53. Rainsford KD, Whitehouse MW. Anti-inflammatory antipyretic salicylic acid esters, with low gastric ulcerogenic activity. Agents Actions 1980; 10: 451-6.
54. Bennett A, Tavares IA. NSAIDs, Cox-2 inhibitors, and the gut. Lancet 1995; 346: 1105.
55. Carefoli E. Intra cellular calcium homeostasis. Ann Rev Biochem 1987; 56: 395-433.
56. Bjarnason I, Williams P, Smethurst P, Peters TJ, Levi AJ. The effect of NSAIDs and prostaglandins on the permeability of the human small intestine. Gut 1986; 27: 1292-7.
57. Bjarnason I, Smethurst P, Fenn GC, Lee CF, Menzies IS, Levi AJ. Misoprostol reduces indomethacin induced changes in human small intestinal permeability. Dig Dis Sci 1989; 34: 407-11.
58. Matthews JB, Smith JA, Tally KJ, Menconi MJ, Nguyen H, Fink MP. Chemical hypoxia increases junctional permeability and activates electrogenic ion transport in human intestinal epithelial monolayers. Surgery 1994; 116: 150-8.